New treatment to remove harmful cholesterol particles from the blood
Official title: Therapeutic Approach to Clear sdLDL from Circulation
Funded at Imetabolic Biopharma Corporation · NIH-10920333 · Data updated 2026-11-12
This study is looking at a new way to help people with heart disease by finding a method to remove harmful small particles in the blood that can still be risky, even when overall cholesterol levels are low, and it focuses on how these particles interact with the liver to improve health outcomes.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Imetabolic Biopharma Corporation NIH-funded |
| Lab location | 1 site (Tempe, United States) |
| Project start | September 15, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $299,504 |
| NIH project number | 1R43HL174270-01 |
| Project ID | NIH-10920333 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with elevated levels of small dense LDL cholesterol and a history of cardiovascular disease.
✕Less likely to help
Patients who have normal cholesterol levels and no cardiovascular disease risk factors may not benefit from this research.
What this research studies
This research focuses on developing a novel therapeutic approach to clear small dense low-density lipoprotein (sdLDL) particles from circulation, which are linked to increased cardiovascular disease risk. The study aims to understand how these particles, despite lowering overall LDL cholesterol levels, continue to pose a threat due to their composition and metabolic behavior. By targeting the excess Apolipoprotein C-III present on sdLDL, the researchers hope to enhance the clearance of these harmful particles from the bloodstream, potentially improving patient outcomes. The methodology involves exploring the interactions between sdLDL and liver receptors to find effective ways to reduce their levels in patients.
Why it matters
Potential benefit: If successful, this research could significantly lower cardiovascular disease risk for patients by effectively removing harmful cholesterol particles from their blood.
How similar studies have gone: While the approach to target sdLDL is innovative, similar strategies targeting cholesterol metabolism have shown promise in other studies.
Where this research is happening
-
Imetabolic Biopharma Corporation
Tempe, United States Active
Researchers
- Principal investigator: Kiernan, Urban a — Imetabolic Biopharma Corporation
- Study coordinator: Kiernan, Urban a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.